# Inhalon Biopharma, Inc.

Canonical: https://abierto.us/vendors/inhalon-biopharma-inc-hfqsj2gmnru6

- UEI: HFQSJ2GMNRU6
- CAGE: 87U21
- Location: Morrisville, NC
- Awards in window: 2 (4 transactions), $5,410,293 obligated, September 16, 2024 to September 22, 2025

## Awarding agencies

- Defense Health Agency: 2 awards, $5,410,293

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $5,410,293

## Competition

- Full and Open Competition: 2 awards

## Largest awards

- HT942525CE039 (definitive contract): $3,175,643, Army Med Res Acq Activity. A Phase 1 Placebo-Controlled Dose-Escalation Safety and Pharmacokinetic Study of IN-007, a Nebulized, PAN-SARS Ace2-Decoy Therapeutic for Pandemic Preparedness. https://www.usaspending.gov/award/CONT_AWD_HT942525CE039_9700_-NONE-_-NONE-/
- HT942524C0076 (definitive contract): $2,234,650, Army Med Res Acq Activity. Developing IN-007 as a Widely Deployable Inhaled Treatment Against Pathogens Utilizing Human ACE2 for Viral Attachment and Entry. https://www.usaspending.gov/award/CONT_AWD_HT942524C0076_9700_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/inhalon-biopharma-inc-hfqsj2gmnru6.